Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 4991-4997

  Bali, Purva ^a   George, Prince ^a   Cohen, Pamela ^b   Tao, Jianguo ^a   Guo, Fei ^a   Sigua, Celia ^a   Vishvanath, Anasuya ^a   Scuto, Anna ^a   Annavarapu, Srinivas ^a   Fiskus, Warren ^a   Moscinski, Lynn ^a   Atadja, Peter ^b   Bhalla, Kapil ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ENZYME INHIBITOR; FLT 3 KINASE; FLT 3 KINASE INHIBITOR; FLT 3 PROTEIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MUTANT FLT 3 RECEPTOR TYROSINE KINASE; MUTANT PROTEIN; MYC PROTEIN; ONCOSTATIN M; PHOSPHOPROTEIN; PROTEASOME; PROTEIN; PROTEIN KINASE B; STAT PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL STRAIN MV4 11; CELL SURVIVAL; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN DNA BINDING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DNA; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; ENZYME INHIBITORS; EXONS; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; G1 PHASE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOCYTIC, ACUTE; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STAUROSPORINE; TIME FACTORS; TRANS-ACTIVATORS;

EID: 4143053577     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0210     Document Type: Article

References (40)

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
2. Stirewalt DL, Radich J. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-65.
3. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002;99:310-8.
4. Tse K-F, Mukheijee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000;14:1766-76.
5. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80.
6. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
7. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-43.
8. Levis M, Allebach J, Tse K-F, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99:3885-91.
9. Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-5.
10. Fabbro D, Ruetz S, Bodis S, et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
11. Tenzer A, Zingg D, Rocha S, et al. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 2001;61:8203-10.
12. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-92.
13. Rocha S, Soengas MS, Lowe SW, et al. Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway. Cell Growth Differ 2000;11:491-9.
14. Estey EH, Fisher T, Giles F, et al. A randomized Phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pt) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3 [abstract]. Blood 2003;102:2270.
15. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002;28:689-93.
16. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
17. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2003;4:13-8.
18. Remiszewski SW. The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 2003;10:2393-402.
19. Atadja P, Gao L, Kwon P, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 2004;64:689-95.
20. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of Imatinib Mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35.
21. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9.
22. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003;9:4483-93.
23. Isaacs HS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
24. Nimmanapalli R, Fuino L, Stobaugh C, Richon VM, Bhalla K. Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood 2003;101:3236-9.
25. Nimmanapalli R, O'Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin (17-AAG). Cancer Res 2002;62:5761-9.
26. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61:1799-804.
27. Fang G, Kim C, Perkins C, et al. CGP57148 (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246-56.
28. L overexpression inhibits Taxol-induced Yama protease activity and apoptosis. Cell Growth Differ 1996;7:1087-94.
29. Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971-84.
30. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002;100:3041-4.
31. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003;9:2140-50.
32. Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 2003;23:4162-73.
33. Mizuki M, Schwäble J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-73.
34. Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003;102:646-51.
35. Stone RM. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 2002;39(Suppl 2):4-10.
36. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715-27.
37. Andreeff M, Konopleva M. Mechanisms of drug resistance in AML. Cancer Treat Res 2002;112:237-62.
38. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002;39(Suppl 3):6-11.
39. Sattler M, Scheijen B, Weisberg E, Griffin JD. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol 2003;532:121-40.
40. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003;3:89-101.